Intrexon | XON - Debt


Intrexon reported $0 in Debt for its fiscal quarter ending in June of 2024.





Debt Change Date
Agenus USD 35.54M 2.34M Mar/2025
Alaunos Therapeutics USD 10.99M 5.78M Mar/2023
Amgen USD 54.6B 17M Dec/2025
Anika Therapeutics USD 0 0 Mar/2025
Arrowhead Research USD 312.77M 53.52M Dec/2025
AstraZeneca USD 33.92B 4.3B Mar/2026
Bristol-Myers Squibb USD 47.14B 3.9B Dec/2025
Gilead Sciences USD 24.94B 5M Dec/2025
GlaxoSmithKline GBP 19.06B 1.34B Mar/2026
Heron Therapeutics USD 149.65M 157K Sep/2024
Incyte USD 39.43M 982K Mar/2026
Intrexon USD 0 13.82M Jun/2024
Karyopharm Therapeutics USD 299.23M 35.14M Dec/2025
Ligand Pharmaceuticals USD 451.49M 494K Dec/2025
MacroGenics USD 37.01M 238K Sep/2025
MannKind USD 367.44M 247.53M Dec/2025
Merck USD 49.34B 7.97B Dec/2025
Novartis USD 47B 11.62B Mar/2026
Rigel Pharmaceuticals USD 59.69M 90K Jun/2024
Roche Holding CHF 33.03B 1.41B Jun/2025
Sangamo BioSciences USD 0 0 Jun/2022
Thermo Fisher Scientific USD 39.39B 3.7B Dec/2025
Veracyte USD 39.65M 799K Dec/2025
Xencor USD 187.75M 118.48M Dec/2025